I agree with you here. For memory Dr Grossman did say early on things were going to plan. But, common sense here, we know it's a complex trial and regardless the spike in cases. Rem_l is for patients on ventilators and the difficult part is convincing them to participate on trial.
investors can argue the company needs to inform shareholders of current situation.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-707
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |